New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
08:13 EDTACTI, TEVATeva, Active Biotech's NERVENTRA 'not favorable' by CHMP
Teva (TEVA) and Active Biotech (ACTI) announced that both companies remain committed to the NERVENTRA clinical development program for multiple sclerosis following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis by the Committee for Medicinal Products for Human Use of the European Medicines Agency. The CHMP has concluded that the risk-benefit profile of NERVENTRA is not favorable at this time. In accordance with European regulations, Teva and Active Biotech intend to request a re-examination of the CHMP opinion. Teva and Active Biotech are focusing on evaluating the CHMPís review and will continue to liaise closely with the EMA in working to make NERVENTRA available as a new treatment option for patients with RRMS in Europe.
News For ACTI;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
06:57 EDTTEVACiti's Abraham lists three reasons to own Allergan
Citi analyst Liav Abraham listed three reasons for why investors should own shares of Allergan (AGN). There is a high likelihood of Allergan's generics division sale to TEVA (TEVA) closing, incremental ant-iinversion Treasury action near term looks increasingly unlikely, implying a high probability of the close of the Pfizer/Allergan merger, and Allergan's fundamental organic growth remains strong, Abraham tells investors in a research note. He keeps a Buy rating on Allergan with a $360 price target.
February 11, 2016
08:44 EDTTEVATeva says plans to invest 'not more than $3B' in M&A in 2016
Subscribe for More Information
08:27 EDTTEVATeva says expects Q1 revenue to continue to be impacted by exchange rates
Subscribe for More Information
08:22 EDTTEVATeva says closing of Actavis Generics business may 'slip into April'
Subscribe for More Information
07:42 EDTTEVATeva sees maintaining current trend in U.S. generic pricing in 2016
Teva (TEVA) says antitrust review ongoing for Actavis (AGN) generics deal. Says potential buyers for divested assets have been identified, integration plans in place. Says U.S. generic prices "continue slightly downward trend," but company does not see the inflationary pricing discussed in the media or the sharp drop in prices other competitors have seen recently. Sees 2016 to maintain current trend in U.S. generic prices. Comments from slides that will be presented on the Q4 earnings conference call.
07:05 EDTTEVATeva says working to close Actavis Generics acquisition by end of Q1
Subscribe for More Information
07:03 EDTTEVATeva sees Q1 adjusted EPS $1.32-$1.36, consensus $1.21
Subscribe for More Information
07:01 EDTTEVATeva reports Q4 adjusted EPS $1.32, consensus $1.29
Subscribe for More Information
05:44 EDTTEVAOptions expected to be active
Subscribe for More Information
February 10, 2016
14:32 EDTTEVANotable companies reporting before tomorrow's open
Subscribe for More Information
09:01 EDTTEVATeva volatility elevated into Q4 and outlook
Teva February weekly call option implied volatility is at 81, February is at 51, March is at 37; compared to its 52-week range of 20 to 41, suggesting large near term price movement into the expected release of Q4 results on February 11.
February 8, 2016
09:34 EDTTEVAPfizer sees decision about potential separation by no later than end 2018
Subscribe for More Information
February 2, 2016
08:12 EDTTEVATeva enters into collaborative research agreement with AbCellera
Subscribe for More Information
08:01 EDTTEVATeva, AbCellera enter agreement to discover rare monoclonal antibodies
Teva and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies. Under the terms of the agreement, AbCellera will receive an upfront payment, research payments, and is eligible to receive undisclosed downstream milestones associated with the development and approval of therapeutic antibodies.
February 1, 2016
08:04 EDTTEVATeva Mylan not seeing same negative trends as Sandoz, says Bernstein
After Novartis (NVS) reported weak results for its generics unit, Sandoz, and blamed it on industry trends, Bernstein quotes Mylan (MYL) and Teva (TEVA) as saying that they are seeing only "slight adjustments back to normal levels" from "mildly favorable" results in 2014 and 2015. Bernstein says that Sandoz has lost a number of fairly profitable products and has had fewer approvals than its peers. Bernstein keeps Outperform ratings on Teva and Mylan.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use